P. 1


|Views: 34|Likes:
Published by Malik Waheed

More info:

Published by: Malik Waheed on May 10, 2011
Copyright:Attribution Non-commercial


Read on Scribd mobile: iPhone, iPad and Android.
download as PPT, PDF, TXT or read online from Scribd
See more
See less






Review of Pathophysiology and Treatment


Chronic inflammatory disease of the airways  Most common childhood chronic disease  Affects ~4.8 million (CDC, 1995)  >100 million days of restricted activity  470,000 hospitalizations/yr


>5000 deaths annually
± Highest in blacks ages 15-24 

Hospitalizations highest in blacks & children

Pathogenesis and Definition  Key points ± Chronic inflammatory disorder of the airways ± Immunohistopathologic features denudation of airway epithelium collagen deposition beneath basement membrane edema mast cell activation .

fatal asthma) ± Eosinophils ± Lymphocytes  Airway inflammation (AI) contributes to hyperresponsiveness. airflow limitation. symptoms & chronicity .± Immunohistopathologic features inflammatory cell infiltration ± Neutrophils (sudden.

edema. mucus plug formation. airway wall remodeling  Atopy is strongest predisposing factor for developing asthma . AI causes types of airflow limitation: ± Bronchoconstriction.

. & epithelial cells). Working definition of asthma (1995. T lymphocytes. eosinophils. NHLBI) ± Asthma is a chronic inflammatory disorder of the airways in which many cells & cellular elements play a role (mast cells. neutrophils. macrophages.

± In susceptible individuals . and coughing. inflammation causes recurrent episodes of wheezing. chest tightness. breathlessness. These episodes are associated with variable airflow obstruction often reversible spontaneously/treatment . particularly at night/early morning.

 Child-onset asthma ± Associated with atopy ± IgE directed against common environmental antigens (house-dust mites. allergy/allergy history associated with continuing asthma through childhood . animal proteins. fungi ± Viral wheezing Infants/children.

 Adult-onset asthma ± Many situations ± Allergens important ± Non-IgE asthma have nasal polyps. aspirin sensitivity or NSAID sensitivity ± Idiosyncratic asthma less understood . sinusitis.

metal removal from workplace may improve symptoms although symptoms persist in some . wood dusts. biological enzymes. plastic resin. Adult-onset asthma ± Occupational exposure animal products.

Airway Inflammation & Lung Function  The cells that influence &/or regulate inflammation results in different types of AI: ± Acute . Abnormal changes may be permanent .persistent level of cell damage & repair.cells activated to cause more persistent inflammatory pattern ± Chronic .early recruitment of cells ± Subacute .

dry air) .Airway Inflammation & Lung Function  Airway hyperresponsiveness ± Exaggerated bronchoconstrictor response ± Post exposure wheezing & dyspnea ± Degree correlates to asthma severity ± Measured by methacholine/histamine inhalation challenge or non-drug stimuli (cold.

of asthma & modification of ai markers reduce symptoms & hyperresponsiveness . Airway hyperresponsiveness ± Correlation to airway inflammation clear but complex airway inflammation markers tx.

irritants) . Airflow limitation ± Acute bronchoconstriction IgE -dependent mediator release from mast cell (leukotrienes. histamine. exercise. tryptase. prostaglandins) aspirin /NSAID non-IgE response (cold air.

mechanisms ?? Airway edema mediators ± increase microvascular permeability/ leakage ± mucosal thickening & airway swelling airway rigidity . Airflow limitation ± Acute bronchoconstriction stress .

 Airflow limitation ± Chronic mucus plug formation secretions & inspissated plugs persistent airflow limitation in severe intractable asthma ± Airway remodeling irreversible component of airflow limitation secondary to structural airway matrix changes .

 Airflow limitation ± Airway remodeling attributed to chronic. severe airway inflammation early intervention with anti-inflammatory therapy suggests prevention of permanent airflow limitation .

Measures of Assessment and Monitoring  Asthma diagnosis criteria ± + episodic symptoms of airflow obstruction ± Airflow obstruction partially reversible ± R/O alternative dx .

. skin. ID potential complications  Asthma Specialist . tract. chest) ± Spirometry to demonstrate reversibility ± Additional studies : evaluate alternative dx. Techniques to establish diagnosis ± History ± Physical exam (resp. ID precipitating factors assess severity.

 Differences from 1991 Expert Panel ± Severity classifications: mild intermittent mild persistent moderate persistent severe persistent ± Questions added to aid dx & assessment ± Referral criteria refined ± PEF diurnal variation recommendations .

Severe Persistent Asthma  Symptoms ± Continual ± Limited physical activity ± Frequent exacerbations ± Frequent nighttime symptoms  Lung Function ± FEV1 or PEF < 60% of predicted ± PEF variability >30% .

< 80% predicted ± PEF variability >30% . may last days ± Nighttime symptoms >1 time/wk  Lung Function ± FEV1 or PEF > 60% . > 2 X/wk.Moderate Persistent Asthma  Symptoms ± Daily symptoms ± Daily use of inhaled short-acting beta2 agonist ± Exacerbations affect activity.

Mild Persistent Asthma  Symptoms ± Symptoms > 2 X/wk but <1 X/day ± Exacerbations may affect activity ± Nighttime symptoms > 2 X/mo  Lung Function ± FEV1 or PEF > 80% predicted ± PEF variability 20-30% .

Mild Intermittent Asthma  Symptoms ± Symptoms < 2 X/wk ± Asymptomatic and normal PEF between exacerbations ± Exacerbations brief (few hrs . intensity may vary ± Nighttime symptoms < 2 X/mo  Lung Function ± FEV1 or PEF > 80% predicted ± PEF variability < 20% .few days).

minimal problems ± Patient/family satisfaction .Asthma Management  Goals of therapy ± Prevent symptoms ± Maintain (near) ³normal´ PF ± Maintain normal activity ± Prevent exacerbations & minimize ER visits/hospitalizations ± Optimal drug tx.

 Recommended monitoring ±S&S ± PFT ± Quality of life/functional status ± Exacerbations ± Drugs ± Patient/provider communication & satisfaction .

Monitor using clinician assessment/pt. self-assessment  Spirometry tests  ± Initial assessment ± Post tx after patient¶s symptoms and PF stabilize ± Minimally Q 1-2 yrs .

 Written action plan based on: ± Signs & symptoms &/or PEF  Patient education: ± Recognition need for additional therapy .

 Patient education: ± How & when to do PF monitoring .

quality of life.Differences from 1991 Panel Added patient/family satisfaction to treatment goals  Periodic assessment of 6 domains of patient health are recommended:  ± S&S. PF. pt. satisfaction . pharmacotherapy. of exacerbations. hx./provider communication. pt.

 PF measurements changes ± Changed from 2 X daily to morning ± If morning <80% of personal best PEF. regardless of severity recognize early deterioration . more frequent monitoring may be desired ± Discussion of inconsistencies in measurement among PF meters added  Emphasis that all pts.

early morning symptoms response to short-acting Beta agonist ± Pulmonary function (spirometry. with moderateto-severe asthma is recommended .Assessment Measures  Asthma treatment effectiveness ± Monitor signs & symptoms . PF) patients with moderate-to-severe persistent asthma should learn how to monitor PEF at home PF during exacerbations in pts.daytime. nocturnal.

Asthma treatment effectiveness
± PF monitoring
long term daily PF monitoring in moderate-tosevere asthma is helpful if long-term PF monitoring is NOT used, short term period of PF monitoring is recommended ± establish individual¶s personal best ± identify time relationships between changes in PF to exposure ± evaluate response to chronic maintenance therapy

Personal best
± 2-3 wk period pt. records early afternoon PEF ± Measure after each use of short-acting beta-2 agonist for symptom relief ± ? course of oral steroids to establish personal best ± Don¶t use outlyer PEF values

Asthma treatment effectiveness
± Monitoring quality of life/functional status
missed work, school activities sleep changes in caregivers activities due to child¶s asthma

± Monitoring asthma exacerbation history
self-treated, or by HC providers

 Asthma treatment effectiveness ± Monitoring asthma exacerbation history unscheduled visits/telephone calls/urgent or emergent care frequency. ICU .length of stay. severity & causes of exacerbations hospitalization info . intubation.

. Asthma treatment effectiveness ± Monitoring Drug Therapy patient compliance inhaler technique frequency of use the short-acting beta2 agonist frequency of oral steroid ³burst´ therapy dose changes of inhaled anti-inflammatory meds.

should be reassessed Q 6 mos ± uncontrolled &/or severe persistent should be seen more often . Asthma treatment effectiveness ± Periodic assessment by clinician and patient clinician assessment ± medical history and physical exam with PFT ± mild intermittent-to-mild persistent asthma under control for 3 mos.

symptoms. use ± periodic self-assessment filled out at the time of the clinic visit .self perception of asthma control. Asthma treatment effectiveness ± Periodic assessment by clinician and patient patient self-assessment ± daily diary . PF.HMO¶s . med. self-skills. satisfaction population based assessment .

Pharmacologic Therapy  Long-term control medications ± corticosteroids inhaled form systemic steroids used to gain prompt control of disease when initiating inhaled tx ± cromolyn sodium or nedocromil mild-to-moderate anti-inflammatory medications (may be used initially in children) preventive tx. prior to exercise or unavoidable exposure to known allergens .

 Long-term control medications ± Long-acting beta2-agonists used concomitantly with anti-inflammatory meds for long-term symptom control especially nocturnal symptoms prevents exercise-induced bronchospasm ± Methylxanthines sustained-release theophylline used as adjuvant to inhaled steroids for prevention of nocturnal symptoms .

 Long-term control medications ± Leukotriene modifiers zafirlukast .5-lipoxygenase inhibitor is alternative therapy to low doses of inhaled steroids/nedocromil/cromolyn alternative tx to low dose inhaled steroids/cromolyn/nedocromil recommended for >12yrs with mild persistent asthma. Further study needed .leukotriene receptor antagonist zileuton .

moderate-to-severe persistent asthma in acute exacerbations or to prevent recurrence of exacerbations . Quick relief medications ± Short acting beta2-agonists . May be alternative to beta2-agonists ± Systemic steroids .relief of acute symptoms ± Anticholinergics .may provide additive benefit to beta2 drugs in severe exacerbation.

airway eosinophilic recruitment. improvement in PEF and spirometry. diminished airway hyperresponsiveness. prevention of exacerbations. chemical mediators .Treatment/Long Term Control  Corticosteroids ± Most potent and effective ± Reduction in symptoms. possible prevention of airway wall remodeling ± Suppresses: cytosine production.

 Corticosteroids ± Dose dependent on product and delivery device ± 2 X/day use is common in moderate-tosevere persistent asthma ± 1 or 2 X/day may be used in mild persistent asthma .

 Cromolyn & nedocromil ± Have distinctive properties ± Similar anti-inflammatory reactions blocks Cl .channels modulate mast cell mediator release modulate eosinophilic recruitment inhibits early and late asthmatic response to antigen challenge .

bradykinin aerosol) nedocromil more potent in inhibiting bronchospasm in the above situations ± Both reduce asthma symptoms improve PF reduce need for short acting beta2 agonists . Cromolyn & nedocromil ± Similar anti-inflammatory reactions inhibits bronchospasm (exercise. cold dry air.

 Cromolyn & nedocromil ± Dosing requirements recommended for both 4 X/day nedocromil effective at 2 X/day ± Clinical response for both is less predictable than steroids ± Both have strong safety profile .

 Long-acting beta-2 agonists ± Relax airway smooth muscle ± Duration of action >12 hrs ± Not used in acute exacerbations ± Adjunct to anti-inflammatory tx for longterm symptom control especially nocturnal symptoms .

 Methylxanthines ± Provides mild-moderate bronchodilation ± Low dose has mild anti-inflammatory action ± Sustained release form used as alternative but not preferred to long-acting beta2 agonists to control nocturnal symptoms ± Use may be necessary because of cost or patient compliance .

 Leukotriene modifiers ± Leukotrienes are potent biochemical mediators released from mast cells. eosinophils. and basophils that: contract bronchial smooth muscle increase vascular permeability increase mucus secretions attract & activate inflammatory cells in airways .

 Leukotriene modifiers ± Zafirlukast & zileuton (oral tabs) improves lung fx and diminishes symptoms & need for short-acting beta2 agonists ± Studies in mild-moderate asthma showing modest improvements ± Alternative to low-dose inhaled steroids for pts. with mild persistent asthma ± Further study in of other groups needed .

 Leukotriene modifiers ± Zafirlukast .leuktriene receptor antagonist attenuates late response to inhaled allergen and post-allergen induced bronchospasm modest improvement in FEV1 (11% > placebo) improved symptoms reduced albuterol use ± Warning .increases warfarin half-life and PT & PTT must be monitored with dose adjustment when indicated .

warfarin. terfenadine and must be monitored . Leukotriene modifiers ± Zileuton .5-lipoxygenase inhibitor provides immediate & sustained improvement in FEV1 (mean 15% > placebo) in mild-tomoderate asthma moderate asthmatics had fewer exacerbations requiring oral steroids attenuates bronchospasm from exercise & from aspirin in sensitive people inhibits metabolism of theophylline.

Asthma Treatment/Quick Relief  Short-acting beta2 agonists ± Relax airway smooth muscle and increase in airflow in <30 minutes ± Drug of choice for treating symptoms and exacerbations and EIB ± Use of >1 canister/mo indicates inadequate control and indicates need to intensify anti-inflammatory tx ± Regularly scheduled use NOT recommended .

 Anticholinergics ± Cholinergic innervation important in regulation of airway smooth muscle tone ± Ipratropium bromide (quaternary derivative of atropine without its¶ side effects) ± Additive benefit with inhaled beta 2agonists in severe asthma exacerbations ± Effectiveness in long-term management not demonstrated .

hydroxychloroquine . gold. Systemic steroids ± speed resolution of airflow obstruction ± reduce rate of relapse  Medications to reduce oral steroid dependence ± Troleandomycin. cyclosporin. dapsone. IV immunoglobulin. methotrexate.

potential toxicity. under supervision of asthma specialist ± Complicated application because of variable effects. Medications to reduce oral steroid dependence ± Recommended use in pts. & limited clinical experience .

beta 2 agonist Q 4-6 hr moderate-to-severe symptoms .Intermittent Asthma  Step 1 ± Short-acting inhaled beta 2 agonists PRN IF NEEDED >2 X/wk PATIENT SHOULD BE MOVED TO THE NEXT STEP OF CARE (exception is EIB or viral infections) ± Viral infections mild symptoms .short course of systemic steroids recommended plus above .

inhaled steroids (low dose) or cromolyn or nedocromil ± Sustained release theophylline alternative but not preferred .Persistent Asthma  Mild. moderate or severe ± Daily long-term control recommended  Mild persistent asthma (step 2 care) ± Daily anti-inflammatory meds .

 Mild persistent asthma (step 2 care) ± Zafirlukast or zileuton considered in pts. >12 yrs ± Quick relief medications must be available short-acting beta 2 agonists intensity depends upon severity of exacerbation .

 Moderate persistent asthma (step 3 care) ± Increase inhaled steroids to medium dose OR ± Add long-acting bronchodilator to a lowmedium dose of inhaled steroids OR ± Increase to medium dose steroid then lower dose & add nedocromil (+/-) .

 Moderate persistent asthma (if not adequately controlled) ± Increase to high dose inhaled steroids & add long-acting bronchodilator (serevent or theophylline) .

 Severe persistent asthma (step 4) ± If not controlled on high dose of inhaled steroids and long-acting bronchodilator ADD oral systemic steroids on a regularly scheduled. long-term basis use lowest dose monitor closely attempt to reduce or take off when control established .

PRN bronchodilators ± Step 2 symptomatic tx > 2x/wk start daily anti-inflammatory therapy .Infants and Young Children  Diagnosis difficult ± If suspected a diagnostic trial of inhaled bronchodilators and anti-inflammatory drugs may be helpful  Infants & young children (<5 yrs) ± Step 1 .

attempt step down therapy ± Step 3 care Higher dose steroids to establish control .step down in 2-3 mos. Infants & young children Trial of cromolyn or nedocromil (low dose inhaled steroids are alternative) Monitor response to anti-inflammatory tx ± After control established. ~ add nedocromil or theophylline instead of increasing steroid .

 Infants & young children ± Exacerbations by viral infections consider systemic steroids ± Consider consultation with asthma specialist in those requiring step 2 care ± Should consult with asthma specialist in those requiring step 3 care .

after initial tx.Emergency Department Treatment Start treatment when asthma exacerbation recognized  While tx is being given:  ± Take a more detailed history ± Complete physical examination ± Perform laboratory studies PEF on presentation. and at frequent intervals) .

± Perform laboratory studies FEV1 or PEF <50% pred. then assess oxygenation by pulse oximetry Lab studies will vary with situation (CBC. ECG). serum theophylline level. electrolytes. These lab studies are NOT routinely recommended . CXR.

moderate-tosevere asthma. (3 tx Q 20 min. continuous therapy an option) Consider anti-cholinergics oral systemic corticosteroids (unresponsive to initial beta2 agonist therapy. inhaled short-acting bronchodilator for all pts.± Treatment: O2 (Sa O2 90-95). people who are on steroids) systemic steroids administered when admitted methylxanthines are not recommended .

children) Antibiotics NOT recommended unless infection present (fever. purulent sputum) CPT NOT recommended Mucolytics NOT recommended Sedation NOT recommended .± Treatment: Aggressive hydration NOT recommended for older children and adults (may be necessary with infants and sm.

Hospitalization  Decision to hospitalize depends upon: duration severity (symptoms & airflow obstruction) course & severity of previous exacerbations medication use at time of exacerbation access (medical care & meds) home conditions psychiatric illness .

treatment ± Intubation shouldn¶t be delayed once ARF is identified Permission hypercapnia is recommended ventilator strategy . Treatment: ± Emergency dept.

You're Reading a Free Preview

/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->